349 related articles for article (PubMed ID: 25387446)
1. Pre-treatment by omalizumab allows allergen immunotherapy in children and young adults with severe allergic asthma.
Lambert N; Guiddir T; Amat F; Just J
Pediatr Allergy Immunol; 2014 Dec; 25(8):829-32. PubMed ID: 25387446
[No Abstract] [Full Text] [Related]
2. [The impact of subcutaneous immunotherapy with Dermatophagoides farinae and Dermatophagoides pteronyssinus on the quality of life of patients with allergic rhinitis and asthma].
Yepes-Núñez JJ; Gómez C; Espinoza Y; Cardona R
Biomedica; 2014; 34(2):282-90. PubMed ID: 24967933
[TBL] [Abstract][Full Text] [Related]
3. Role of immunmodulators in allergen-specific immunotherapy.
Kopp MV
Allergy; 2011 Jun; 66(6):792-7. PubMed ID: 21332502
[TBL] [Abstract][Full Text] [Related]
4. Use of omalizumab to improve desensitization safety in allergen immunotherapy.
Larenas-Linnemann D; Wahn U; Kopp M
J Allergy Clin Immunol; 2014 Mar; 133(3):937-937.e2. PubMed ID: 24581432
[No Abstract] [Full Text] [Related]
5. Allergen immunotherapy and asthma.
Tosca MA; Olcese R; Licari A; Ciprandi G
Pediatr Allergy Immunol; 2020 Feb; 31 Suppl 24():46-48. PubMed ID: 32017211
[TBL] [Abstract][Full Text] [Related]
6. Semi-depot house-dust mite allergen extract for Chinese with allergic rhinitis and asthma.
Li X; Wang X; Lin X; Xu G; Tao Z; Jiang W; Cheng L; Guo Y; Lai H; Shen K
Am J Rhinol Allergy; 2016 May; 30(3):201-8. PubMed ID: 27216351
[TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity of immunotherapy with Bet v 1-derived contiguous overlapping peptides.
Spertini F; Perrin Y; Audran R; Pellaton C; Boudousquié C; Barbier N; Thierry AC; Charlon V; Reymond C
J Allergy Clin Immunol; 2014 Jul; 134(1):239-240.e13. PubMed ID: 24797422
[No Abstract] [Full Text] [Related]
8. Omalizumab for the treatment of inadequately controlled allergic rhinitis: a systematic review and meta-analysis of randomized clinical trials.
Tsabouri S; Tseretopoulou X; Priftis K; Ntzani EE
J Allergy Clin Immunol Pract; 2014; 2(3):332-40.e1. PubMed ID: 24811026
[TBL] [Abstract][Full Text] [Related]
9. Effect of tonsillectomy on the efficacy of house dust mite sublingual immunotherapy.
Refaat M; Ashour ZA; Farres MN; Eissa AM; Elsayed MM
Allergol Immunopathol (Madr); 2015; 43(1):108-11. PubMed ID: 24388811
[No Abstract] [Full Text] [Related]
10. Allergic rhinitis and asthma connection: treatment implications.
Greenberger PA
Allergy Asthma Proc; 2008; 29(6):557-64. PubMed ID: 19173782
[TBL] [Abstract][Full Text] [Related]
11. Transient impact of omalizumab in pollen allergic patients undergoing specific immunotherapy.
Kopp MV; Hamelmann E; Bendiks M; Zielen S; Kamin W; Bergmann KC; Klein C; Wahn U;
Pediatr Allergy Immunol; 2013 Aug; 24(5):427-33. PubMed ID: 23799935
[TBL] [Abstract][Full Text] [Related]
12. [An analysis of the subcutaneous immunotherapy on the pulmonary function and symptoms of asthma and rhinitis in children].
Wu SJ; Chen S; Chen B; Wang L; Zeng X
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2017 Sep; 31(17):1352-1355. PubMed ID: 29798230
[No Abstract] [Full Text] [Related]
13. Anti-immunoglobulin E monoclonal antibody administered with immunotherapy.
Parks KW; Casale TB
Allergy Asthma Proc; 2006; 27(2 Suppl 1):S33-6. PubMed ID: 16722330
[TBL] [Abstract][Full Text] [Related]
14. Pet dander and difficult-to-control asthma: Therapeutic options.
Ling M; Long AA
Allergy Asthma Proc; 2010; 31(5):385-91. PubMed ID: 20929605
[TBL] [Abstract][Full Text] [Related]
15. Specific immunotherapy for rhinitis and asthma with a subcutaneous hypoallergenic high-dose house dust mite extract: results of a 9-month therapy.
El-Qutob D; Moreno F; Subtil-Rodríguez A
Immunotherapy; 2016 Jul; 8(8):867-76. PubMed ID: 27188493
[TBL] [Abstract][Full Text] [Related]
16. [Research progress of monoclonal antibody omalizumab in the treatment of allergic rhinitis].
Qiu X; Wang H
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2015 Feb; 50(2):166-8. PubMed ID: 25916543
[No Abstract] [Full Text] [Related]
17. Changes in IL-10 and specific antibodies associated to successful Dermatophagoides pteronyssinus immunotherapy in children during the first year of treatment.
Martín-Muñoz MF; Pineda F; Muiños T; Fontan M; Nevot S; Bosque M; Jurado Palomo J; Torredemer A; Valdesoiro L; Martinez Cañavate AM; Pedemonte Marco C;
Allergol Immunopathol (Madr); 2013; 41(1):4-10. PubMed ID: 22321665
[TBL] [Abstract][Full Text] [Related]
18. Long-term effects of allergen-specific subcutaneous immunotherapy for house dust mite induced allergic rhinitis.
Sahin E; Dizdar D; Dinc ME; Cirik AA
J Laryngol Otol; 2017 Nov; 131(11):997-1001. PubMed ID: 29037263
[TBL] [Abstract][Full Text] [Related]
19. Treatment with a combination of anti-IgE and specific immunotherapy for allergic rhinitis and asthma.
Hamelmann E; Rolinck-Werninghaus C; Wahn U; Kopp MV
Arb Paul Ehrlich Inst Bundesinstitut Impfstoffe Biomed Arzneim Langen Hess; 2009; 96():303-13; discussion 313-5. PubMed ID: 20799475
[TBL] [Abstract][Full Text] [Related]
20. Oral immunotherapy and anti-IgE antibody-adjunctive treatment for food allergy.
Nadeau KC; Kohli A; Iyengar S; DeKruyff RH; Umetsu DT
Immunol Allergy Clin North Am; 2012 Feb; 32(1):111-33. PubMed ID: 22244236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
